25 XP   0   0   10

Sinphar Pharmaceutical Co Ltd
Buy, Hold or Sell?

Let's analyse Sinphar together

PenkeI guess you are interested in Sinphar Pharmaceutical Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Sinphar Pharmaceutical Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Sinphar Pharmaceutical Co Ltd

I send you an email if I find something interesting about Sinphar Pharmaceutical Co Ltd.

Quick analysis of Sinphar (30 sec.)










What can you expect buying and holding a share of Sinphar? (30 sec.)

How much money do you get?

How much money do you get?
NT$0.00
When do you have the money?
1 year
How often do you get paid?
67.5%

What is your share worth?

Current worth
NT$20.26
Expected worth in 1 year
NT$21.34
How sure are you?
55.0%

+ What do you gain per year?

Total Gains per Share
NT$1.08
Return On Investment
3.0%

For what price can you sell your share?

Current Price per Share
NT$36.50
Expected price per share
NT$34.70 - NT$41.10
How sure are you?
50%

1. Valuation of Sinphar (5 min.)




Live pricePrice per Share (EOD)

NT$36.50

Intrinsic Value Per Share

NT$8.87 - NT$26.50

Total Value Per Share

NT$29.13 - NT$46.76

2. Growth of Sinphar (5 min.)




Is Sinphar growing?

Current yearPrevious yearGrowGrow %
How rich?$106.3m$100.1m$2.6m2.6%

How much money is Sinphar making?

Current yearPrevious yearGrowGrow %
Making money$2.9m$1.7m$1.1m40.1%
Net Profit Margin12.7%8.0%--

How much money comes from the company's main activities?

3. Financial Health of Sinphar (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#372 / 1031

Most Revenue
#195 / 1031

Most Profit
#113 / 1031

Most Efficient
#109 / 1031

What can you expect buying and holding a share of Sinphar? (5 min.)

Welcome investor! Sinphar's management wants to use your money to grow the business. In return you get a share of Sinphar.

What can you expect buying and holding a share of Sinphar?

First you should know what it really means to hold a share of Sinphar. And how you can make/lose money.

Speculation

The Price per Share of Sinphar is NT$36.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Sinphar.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sinphar, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is NT$20.26. Based on the TTM, the Book Value Change Per Share is NT$0.27 per quarter. Based on the YOY, the Book Value Change Per Share is NT$0.21 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is NT$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Sinphar.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 NT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per Share
Usd Eps0.020.1%0.020.1%0.010.0%0.010.0%0.000.0%
Usd Book Value Change Per Share0.020.1%0.010.0%0.010.0%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.010.0%
Usd Total Gains Per Share0.020.1%0.010.0%0.010.0%0.000.0%0.000.0%
Usd Price Per Share1.06-1.04-0.94-0.91-0.94-
Price to Earnings Ratio12.96-14.12-44.00-28.48-5.77-
Price-to-Total Gains Ratio43.85-30.89--12.79--2.73--43.80-
Price to Book Ratio1.68-1.70-1.58-1.52-1.47-
Price-to-Total Gains Ratio43.85-30.89--12.79--2.73--43.80-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.14245
Number of shares875
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.00
Usd Total Gains Per Share0.010.00
Gains per Quarter (875 shares)7.393.26
Gains per Year (875 shares)29.5613.02
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10302014-13
20595027-116
30898041-229
4011811055-342
5014814068-355
6017717082-468
7020720096-581
80236230110-594
90266260123-6107
100296290137-7120

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%10.02.00.083.3%14.06.00.070.0%24.09.07.060.0%47.09.07.074.6%
Book Value Change Per Share3.01.00.075.0%8.04.00.066.7%10.010.00.050.0%16.024.00.040.0%32.031.00.050.8%
Dividend per Share0.00.04.00.0%7.00.05.058.3%14.00.06.070.0%27.00.013.067.5%35.00.028.055.6%
Total Gains per Share3.01.00.075.0%8.04.00.066.7%12.08.00.060.0%22.018.00.055.0%39.024.00.061.9%

Fundamentals of Sinphar

About Sinphar Pharmaceutical Co Ltd

Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, researches, develops, manufactures, and sells therapeutic drugs, health care foods, and medical beauty products in Taiwan, Mainland China, the United States, Vietnam, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Other. It produces anti-cancer pharmaceuticals, such as injections, solid reagents, and hormone reagents; and tablets, soft gel capsules and powder and canned special nutrient products. The company also offers shampoo, body wash, tonic water, lotions, moisturizers, sunscreen lotions, and serums; and pharmaceutical packaging products, such as eye drop bottles, dry canisters, tablet bottles, and various medical grade plastic containers. In addition, it provides plant extracts and functional foods; and OEM services, such as product design, manufacturing, etc. to manufacturers, as well as testing and development of food, drug, and cosmetic products. The company was incorporated in 1977 and is headquartered in Yilan City, Taiwan.

Fundamental data was last updated by Penke on 2024-03-25 11:00:09.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Sinphar Pharmaceutical Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Sinphar earns for each NT$1 of revenue.

  • Above 10% is considered healthy but always compare Sinphar to the Biotechnology industry mean.
  • A Net Profit Margin of 14.7% means that NT$0.15 for each NT$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Sinphar Pharmaceutical Co Ltd:

  • The MRQ is 14.7%. The company is making a huge profit. +2
  • The TTM is 12.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ14.7%TTM12.7%+2.0%
TTM12.7%YOY8.0%+4.7%
TTM12.7%5Y3.6%+9.1%
5Y3.6%10Y3.1%+0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.7%-159.2%+173.9%
TTM12.7%-202.3%+215.0%
YOY8.0%-263.0%+271.0%
5Y3.6%-452.4%+456.0%
10Y3.1%-589.0%+592.1%
1.1.2. Return on Assets

Shows how efficient Sinphar is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Sinphar to the Biotechnology industry mean.
  • 1.8% Return on Assets means that Sinphar generated NT$0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Sinphar Pharmaceutical Co Ltd:

  • The MRQ is 1.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.8%TTM1.5%+0.2%
TTM1.5%YOY0.9%+0.6%
TTM1.5%5Y0.4%+1.1%
5Y0.4%10Y0.4%+0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8%-12.5%+14.3%
TTM1.5%-12.2%+13.7%
YOY0.9%-11.2%+12.1%
5Y0.4%-13.3%+13.7%
10Y0.4%-14.6%+15.0%
1.1.3. Return on Equity

Shows how efficient Sinphar is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Sinphar to the Biotechnology industry mean.
  • 3.5% Return on Equity means Sinphar generated NT$0.04 for each NT$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Sinphar Pharmaceutical Co Ltd:

  • The MRQ is 3.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.1%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.5%TTM3.1%+0.4%
TTM3.1%YOY2.0%+1.1%
TTM3.1%5Y0.9%+2.2%
5Y0.9%10Y0.7%+0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5%-16.0%+19.5%
TTM3.1%-15.8%+18.9%
YOY2.0%-13.9%+15.9%
5Y0.9%-18.2%+19.1%
10Y0.7%-19.1%+19.8%

1.2. Operating Efficiency of Sinphar Pharmaceutical Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Sinphar is operating .

  • Measures how much profit Sinphar makes for each NT$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Sinphar to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated NT$0.00  for each NT$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Sinphar Pharmaceutical Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1.1%-1.1%
TTM1.1%YOY7.1%-6.0%
TTM1.1%5Y0.9%+0.2%
5Y0.9%10Y-0.5%+1.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM1.1%-208.5%+209.6%
YOY7.1%-280.2%+287.3%
5Y0.9%-459.9%+460.8%
10Y-0.5%-596.9%+596.4%
1.2.2. Operating Ratio

Measures how efficient Sinphar is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.47 means that the operating costs are NT$1.47 for each NT$1 in net sales.

Let's take a look of the Operating Ratio trends of Sinphar Pharmaceutical Co Ltd:

  • The MRQ is 1.473. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.535. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.473TTM1.535-0.062
TTM1.535YOY1.546-0.011
TTM1.5355Y1.631-0.096
5Y1.63110Y1.320+0.311
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4732.817-1.344
TTM1.5353.181-1.646
YOY1.5463.609-2.063
5Y1.6315.554-3.923
10Y1.3207.396-6.076

1.3. Liquidity of Sinphar Pharmaceutical Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Sinphar is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.20 means the company has NT$2.20 in assets for each NT$1 in short-term debts.

Let's take a look of the Current Ratio trends of Sinphar Pharmaceutical Co Ltd:

  • The MRQ is 2.199. The company is able to pay all its short-term debts. +1
  • The TTM is 2.107. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.199TTM2.107+0.091
TTM2.107YOY2.043+0.064
TTM2.1075Y1.935+0.172
5Y1.93510Y1.529+0.406
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1993.987-1.788
TTM2.1074.440-2.333
YOY2.0435.569-3.526
5Y1.9356.158-4.223
10Y1.5296.492-4.963
1.3.2. Quick Ratio

Measures if Sinphar is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Sinphar to the Biotechnology industry mean.
  • A Quick Ratio of 0.40 means the company can pay off NT$0.40 for each NT$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Sinphar Pharmaceutical Co Ltd:

  • The MRQ is 0.402. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.439. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.402TTM0.439-0.037
TTM0.439YOY0.492-0.053
TTM0.4395Y0.442-0.003
5Y0.44210Y0.511-0.069
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4023.653-3.251
TTM0.4394.158-3.719
YOY0.4925.515-5.023
5Y0.4426.012-5.570
10Y0.5116.206-5.695

1.4. Solvency of Sinphar Pharmaceutical Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Sinphar assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Sinphar to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.46 means that Sinphar assets are financed with 45.6% credit (debt) and the remaining percentage (100% - 45.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Sinphar Pharmaceutical Co Ltd:

  • The MRQ is 0.456. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.460. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.456TTM0.460-0.004
TTM0.460YOY0.486-0.025
TTM0.4605Y0.478-0.018
5Y0.47810Y0.433+0.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4560.336+0.120
TTM0.4600.330+0.130
YOY0.4860.267+0.219
5Y0.4780.367+0.111
10Y0.4330.378+0.055
1.4.2. Debt to Equity Ratio

Measures if Sinphar is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Sinphar to the Biotechnology industry mean.
  • A Debt to Equity ratio of 92.1% means that company has NT$0.92 debt for each NT$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Sinphar Pharmaceutical Co Ltd:

  • The MRQ is 0.921. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.929. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.921TTM0.929-0.008
TTM0.929YOY1.052-0.123
TTM0.9295Y1.043-0.114
5Y1.04310Y0.903+0.140
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9210.376+0.545
TTM0.9290.398+0.531
YOY1.0520.334+0.718
5Y1.0430.431+0.612
10Y0.9030.476+0.427

2. Market Valuation of Sinphar Pharmaceutical Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every NT$1 in earnings Sinphar generates.

  • Above 15 is considered overpriced but always compare Sinphar to the Biotechnology industry mean.
  • A PE ratio of 12.96 means the investor is paying NT$12.96 for every NT$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Sinphar Pharmaceutical Co Ltd:

  • The EOD is 13.932. Based on the earnings, the company is underpriced. +1
  • The MRQ is 12.959. Based on the earnings, the company is underpriced. +1
  • The TTM is 14.120. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD13.932MRQ12.959+0.973
MRQ12.959TTM14.120-1.161
TTM14.120YOY43.999-29.879
TTM14.1205Y28.479-14.359
5Y28.47910Y5.769+22.710
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD13.932-2.697+16.629
MRQ12.959-2.422+15.381
TTM14.120-2.709+16.829
YOY43.999-4.116+48.115
5Y28.479-6.257+34.736
10Y5.769-6.478+12.247
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Sinphar Pharmaceutical Co Ltd:

  • The EOD is 26.447. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 24.599. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is -0.750. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD26.447MRQ24.599+1.848
MRQ24.599TTM-0.750+25.349
TTM-0.750YOY0.639-1.389
TTM-0.7505Y49.757-50.507
5Y49.75710Y26.538+23.219
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD26.447-3.344+29.791
MRQ24.599-2.939+27.538
TTM-0.750-3.486+2.736
YOY0.639-5.592+6.231
5Y49.757-8.464+58.221
10Y26.538-8.872+35.410
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Sinphar is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.68 means the investor is paying NT$1.68 for each NT$1 in book value.

Let's take a look of the Price to Book Ratio trends of Sinphar Pharmaceutical Co Ltd:

  • The EOD is 1.802. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.676. Based on the equity, the company is underpriced. +1
  • The TTM is 1.701. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.802MRQ1.676+0.126
MRQ1.676TTM1.701-0.026
TTM1.701YOY1.575+0.126
TTM1.7015Y1.521+0.181
5Y1.52110Y1.465+0.055
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.8022.198-0.396
MRQ1.6762.042-0.366
TTM1.7012.121-0.420
YOY1.5752.907-1.332
5Y1.5213.682-2.161
10Y1.4654.114-2.649
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Sinphar Pharmaceutical Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.7740.270+187%0.208+272%-0.006+101%-0.014+102%
Book Value Per Share--20.25919.598+3%19.084+6%19.161+6%20.658-2%
Current Ratio--2.1992.107+4%2.043+8%1.935+14%1.529+44%
Debt To Asset Ratio--0.4560.460-1%0.486-6%0.478-5%0.433+5%
Debt To Equity Ratio--0.9210.929-1%1.052-12%1.043-12%0.903+2%
Dividend Per Share----0%0.150-100%0.125-100%0.169-100%
Eps--0.6550.602+9%0.335+96%0.172+281%0.136+380%
Free Cash Flow Per Share--0.345-0.007+102%0.405-15%-0.008+102%-0.125+136%
Free Cash Flow To Equity Per Share--0.345-0.065+119%0.013+2614%0.088+292%0.122+183%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.825+21%
Intrinsic Value_10Y_max--26.501--------
Intrinsic Value_10Y_min--8.874--------
Intrinsic Value_1Y_max--0.796--------
Intrinsic Value_1Y_min---0.267--------
Intrinsic Value_3Y_max--3.808--------
Intrinsic Value_3Y_min--0.195--------
Intrinsic Value_5Y_max--8.530--------
Intrinsic Value_5Y_min--1.745--------
Market Cap6121853000.000+7%5694161900.0005587239125.000+2%5042142625.000+13%4872788590.000+17%5056287438.120+13%
Net Profit Margin--0.1470.127+16%0.080+84%0.036+308%0.031+377%
Operating Margin---0.011-100%0.071-100%0.009-100%-0.0050%
Operating Ratio--1.4731.535-4%1.546-5%1.631-10%1.320+12%
Pb Ratio1.802+7%1.6761.701-2%1.575+6%1.521+10%1.465+14%
Pe Ratio13.932+7%12.95914.120-8%43.999-71%28.479-54%5.769+125%
Price Per Share36.500+7%33.95033.313+2%30.063+13%29.053+17%30.121+13%
Price To Free Cash Flow Ratio26.447+7%24.599-0.750+103%0.639+3749%49.757-51%26.538-7%
Price To Total Gains Ratio47.146+7%43.85230.889+42%-12.785+129%-2.727+106%-43.804+200%
Quick Ratio--0.4020.439-9%0.492-18%0.442-9%0.511-21%
Return On Assets--0.0180.015+14%0.009+95%0.004+293%0.004+384%
Return On Equity--0.0350.031+14%0.020+81%0.009+287%0.007+386%
Total Gains Per Share--0.7740.270+187%0.358+116%0.119+551%0.154+401%
Usd Book Value--106353456.200102881480.225+3%100183498.475+6%100589462.605+6%108574637.225-2%
Usd Book Value Change Per Share--0.0240.008+187%0.007+272%0.000+101%0.000+102%
Usd Book Value Per Share--0.6340.613+3%0.597+6%0.600+6%0.647-2%
Usd Dividend Per Share----0%0.005-100%0.004-100%0.005-100%
Usd Eps--0.0200.019+9%0.010+96%0.005+281%0.004+380%
Usd Free Cash Flow--1811299.700-35728.950+102%2127249.725-15%-41020.215+102%-640066.220+135%
Usd Free Cash Flow Per Share--0.0110.000+102%0.013-15%0.000+102%-0.004+136%
Usd Free Cash Flow To Equity Per Share--0.011-0.002+119%0.000+2614%0.003+292%0.004+183%
Usd Market Cap191613998.900+7%178227267.470174880584.613+2%157819064.163+13%152518282.867+17%158261796.813+13%
Usd Price Per Share1.142+7%1.0631.043+2%0.941+13%0.909+17%0.943+13%
Usd Profit--3438273.7002935705.250+17%1757839.300+96%856258.450+302%693573.570+396%
Usd Revenue--23430147.10023184958.550+1%22353294.075+5%20401562.230+15%19053248.218+23%
Usd Total Gains Per Share--0.0240.008+187%0.011+116%0.004+551%0.005+401%
 EOD+4 -4MRQTTM+29 -4YOY+25 -105Y+29 -610Y+23 -12

3.2. Fundamental Score

Let's check the fundamental score of Sinphar Pharmaceutical Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1513.932
Price to Book Ratio (EOD)Between0-11.802
Net Profit Margin (MRQ)Greater than00.147
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.402
Current Ratio (MRQ)Greater than12.199
Debt to Asset Ratio (MRQ)Less than10.456
Debt to Equity Ratio (MRQ)Less than10.921
Return on Equity (MRQ)Greater than0.150.035
Return on Assets (MRQ)Greater than0.050.018
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Sinphar Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.749
Ma 20Greater thanMa 5035.280
Ma 50Greater thanMa 10033.962
Ma 100Greater thanMa 20033.699
OpenGreater thanClose36.650
Total5/5 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Minority Interest  31,548-21,9039,64591110,55655111,107-24,021-12,914



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in TWD. All numbers in thousands.

Summary
Total Assets6,251,081
Total Liabilities2,853,207
Total Stockholder Equity3,098,338
 As reported
Total Liabilities 2,853,207
Total Stockholder Equity+ 3,098,338
Total Assets = 6,251,081

Assets

Total Assets6,251,081
Total Current Assets2,648,605
Long-term Assets3,602,476
Total Current Assets
Cash And Cash Equivalents 1,074,489
Short-term Investments 6,660
Net Receivables 477,252
Inventory 839,194
Other Current Assets 5,747
Total Current Assets  (as reported)2,648,605
Total Current Assets  (calculated)2,403,342
+/- 245,263
Long-term Assets
Property Plant Equipment 3,277,734
Long-term Assets Other 33,527
Long-term Assets  (as reported)3,602,476
Long-term Assets  (calculated)3,311,261
+/- 291,215

Liabilities & Shareholders' Equity

Total Current Liabilities1,204,694
Long-term Liabilities1,648,513
Total Stockholder Equity3,098,338
Total Current Liabilities
Short Long Term Debt 450,878
Accounts payable 291,208
Other Current Liabilities 37,361
Total Current Liabilities  (as reported)1,204,694
Total Current Liabilities  (calculated)779,447
+/- 425,247
Long-term Liabilities
Long term Debt 1,494,142
Long-term Liabilities Other 118,819
Long-term Liabilities  (as reported)1,648,513
Long-term Liabilities  (calculated)1,612,961
+/- 35,552
Total Stockholder Equity
Retained Earnings 369,802
Total Stockholder Equity (as reported)3,098,338
Total Stockholder Equity (calculated)369,802
+/- 2,728,536
Other
Capital Stock1,677,221
Common Stock Shares Outstanding 167,722
Net Debt 870,531
Net Invested Capital 5,043,358
Net Working Capital 1,443,911
Property Plant and Equipment Gross 3,277,734



Balance Sheet

Currency in TWD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-06-302006-06-302005-06-30
> Total Assets 
2,341,389
2,696,589
2,987,714
3,310,299
3,671,640
3,332,055
3,593,161
3,587,398
3,558,298
3,593,875
3,584,314
3,565,715
3,690,296
3,665,157
3,713,199
3,766,070
3,694,819
3,684,125
4,638,603
4,159,055
4,290,691
4,499,163
4,569,596
5,176,513
5,259,617
5,445,223
5,703,449
5,728,285
5,795,403
5,610,757
6,463,903
6,428,064
6,290,915
6,054,169
6,386,654
6,210,392
6,269,144
6,392,138
6,206,418
5,980,109
5,970,976
5,998,894
6,043,100
6,016,089
6,033,957
5,941,914
5,878,127
5,911,260
6,231,659
6,045,600
5,916,524
6,189,427
6,263,753
6,141,810
6,126,915
6,427,070
6,322,747
6,200,332
6,220,931
6,356,954
6,223,033
6,135,044
6,185,191
5,969,292
5,976,210
6,162,103
6,251,081
6,251,0816,162,1035,976,2105,969,2926,185,1916,135,0446,223,0336,356,9546,220,9316,200,3326,322,7476,427,0706,126,9156,141,8106,263,7536,189,4275,916,5246,045,6006,231,6595,911,2605,878,1275,941,9146,033,9576,016,0896,043,1005,998,8945,970,9765,980,1096,206,4186,392,1386,269,1446,210,3926,386,6546,054,1696,290,9156,428,0646,463,9035,610,7575,795,4035,728,2855,703,4495,445,2235,259,6175,176,5134,569,5964,499,1634,290,6914,159,0554,638,6033,684,1253,694,8193,766,0703,713,1993,665,1573,690,2963,565,7153,584,3143,593,8753,558,2983,587,3983,593,1613,332,0553,671,6403,310,2992,987,7142,696,5892,341,389
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,362,839
2,189,978
2,181,401
2,199,826
2,258,900
2,203,783
2,288,649
2,217,228
2,121,733
2,181,709
2,520,953
2,349,525
2,261,999
2,569,828
2,670,342
2,547,413
2,539,635
2,857,681
2,814,582
2,671,442
2,703,349
2,853,298
2,780,195
2,722,202
2,778,451
2,567,736
2,538,055
2,579,601
2,648,605
2,648,6052,579,6012,538,0552,567,7362,778,4512,722,2022,780,1952,853,2982,703,3492,671,4422,814,5822,857,6812,539,6352,547,4132,670,3422,569,8282,261,9992,349,5252,520,9532,181,7092,121,7332,217,2282,288,6492,203,7832,258,9002,199,8262,181,4012,189,9782,362,83900000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,094,920
1,033,020
1,035,337
1,027,199
1,070,188
1,016,246
1,079,516
1,019,764
958,520
907,866
1,191,665
1,034,533
840,718
1,101,475
1,118,720
1,087,002
1,143,769
1,392,275
1,323,727
1,209,365
1,194,785
1,289,385
1,251,910
1,198,455
1,237,556
962,479
1,017,460
995,134
1,074,489
1,074,489995,1341,017,460962,4791,237,5561,198,4551,251,9101,289,3851,194,7851,209,3651,323,7271,392,2751,143,7691,087,0021,118,7201,101,475840,7181,034,5331,191,665907,866958,5201,019,7641,079,5161,016,2461,070,1881,027,1991,035,3371,033,0201,094,92000000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
45,212
50,730
60,043
80,386
94,308
75,281
81,297
62,104
9,956
29,560
43,732
53,205
45,405
91,760
90,480
49,350
50,430
50,100
49,750
49,710
50,100
51,720
51,050
6,660
6,660
6,660
6,660
6,660
6,660
6,6606,6606,6606,6606,6606,66051,05051,72050,10049,71049,75050,10050,43049,35090,48091,76045,40553,20543,73229,5609,95662,10481,29775,28194,30880,38660,04350,73045,21200000000000000000000000000000000000000
       Net Receivables 
468,065
475,743
481,682
492,649
462,822
420,135
449,296
447,582
441,365
424,291
409,152
425,651
434,582
428,546
387,823
452,495
397,930
355,176
390,382
437,995
440,719
428,114
443,488
438,774
471,661
446,865
521,177
499,063
519,015
458,036
558,623
493,012
482,751
453,725
562,538
492,084
519,603
473,170
572,486
480,363
466,801
471,875
545,603
530,741
539,297
523,026
593,521
442,990
425,860
413,987
658,958
628,972
588,292
561,788
495,901
549,645
538,333
535,635
592,972
644,636
613,704
626,663
685,189
543,446
636,868
474,706
477,252
477,252474,706636,868543,446685,189626,663613,704644,636592,972535,635538,333549,645495,901561,788588,292628,972658,958413,987425,860442,990593,521523,026539,297530,741545,603471,875466,801480,363572,486473,170519,603492,084562,538453,725482,751493,012558,623458,036519,015499,063521,177446,865471,661438,774443,488428,114440,719437,995390,382355,176397,930452,495387,823428,546434,582425,651409,152424,291441,365447,582449,296420,135462,822492,649481,682475,743468,065
       Inventory 
0
324,224
0
0
393,374
397,082
378,855
409,485
372,172
395,176
400,481
436,098
409,483
415,803
420,168
386,941
409,217
432,440
440,593
436,080
423,228
436,994
518,447
581,918
617,381
560,903
734,554
733,676
733,899
813,778
861,872
821,962
766,336
783,763
697,559
706,075
701,389
643,970
611,564
593,213
583,313
587,008
522,425
535,770
537,495
548,836
488,053
518,976
558,701
547,710
671,513
691,260
811,606
833,753
839,250
824,691
878,272
853,763
820,621
840,314
838,554
863,700
737,013
798,967
854,942
816,984
839,194
839,194816,984854,942798,967737,013863,700838,554840,314820,621853,763878,272824,691839,250833,753811,606691,260671,513547,710558,701518,976488,053548,836537,495535,770522,425587,008583,313593,213611,564643,970701,389706,075697,559783,763766,336821,962861,872813,778733,899733,676734,554560,903617,381581,918518,447436,994423,228436,080440,593432,440409,217386,941420,168415,803409,483436,098400,481395,176372,172409,485378,855397,082393,37400324,2240
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,729,551
3,710,706
3,696,075
3,654,525
3,619,599
3,593,411
3,594,397
3,587,280
3,569,389
3,508,165
3,528,890
3,517,582
3,503,656
3,442,838
3,412,842
3,406,740
3,401,556
3,438,155
3,582,502
3,602,476
3,602,4763,582,5023,438,1553,401,5563,406,7403,412,8423,442,8383,503,6563,517,5823,528,8903,508,1653,569,3893,587,2803,594,3973,593,4113,619,5993,654,5253,696,0753,710,7063,729,55100000000000000000000000000000000000000000000000
       Property Plant Equipment 
1,092,682
1,316,741
1,509,489
1,853,021
1,864,907
1,912,018
1,931,255
1,965,891
1,991,618
1,986,823
2,034,906
2,086,538
2,207,826
2,189,002
2,181,092
2,190,355
2,173,408
2,185,942
2,519,580
2,602,891
2,644,948
2,702,621
2,729,135
2,849,330
3,000,667
3,088,501
3,153,532
3,206,373
3,223,326
3,262,251
3,295,504
3,286,211
3,280,895
3,387,798
3,386,624
3,386,226
3,386,250
3,344,090
3,357,714
3,321,269
3,324,247
3,326,663
3,336,626
3,349,186
3,315,522
3,260,555
3,346,664
3,345,324
3,347,363
3,320,084
3,322,809
3,286,721
3,262,984
3,268,427
3,287,319
3,250,806
3,219,662
3,198,538
3,223,811
3,232,873
3,189,742
3,211,438
3,204,384
3,207,319
3,197,987
3,266,672
3,277,734
3,277,7343,266,6723,197,9873,207,3193,204,3843,211,4383,189,7423,232,8733,223,8113,198,5383,219,6623,250,8063,287,3193,268,4273,262,9843,286,7213,322,8093,320,0843,347,3633,345,3243,346,6643,260,5553,315,5223,349,1863,336,6263,326,6633,324,2473,321,2693,357,7143,344,0903,386,2503,386,2263,386,6243,387,7983,280,8953,286,2113,295,5043,262,2513,223,3263,206,3733,153,5323,088,5013,000,6672,849,3302,729,1352,702,6212,644,9482,602,8912,519,5802,185,9422,173,4082,190,3552,181,0922,189,0022,207,8262,086,5382,034,9061,986,8231,991,6181,965,8911,931,2551,912,0181,864,9071,853,0211,509,4891,316,7411,092,682
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
90,435
83,012
85,907
105,181
102,651
116,346
92,605
96,805
58,868
66,444
59,606
47,308
30,388
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000030,38847,30859,60666,44458,86896,80592,605116,346102,651105,18185,90783,01290,43500000000000000000000000000000000000000
       Intangible Assets 
129,102
106,125
97,678
89,949
87,727
89,597
110,972
110,410
103,059
100,752
80,529
78,848
78,085
77,585
74,623
73,806
71,579
72,670
74,952
72,500
56,870
66,699
67,305
37,895
70,938
69,279
39,993
47,221
46,237
71,053
185,653
179,988
173,052
165,777
334,928
330,119
321,919
315,749
304,003
296,148
284,906
272,750
260,552
250,307
239,842
228,356
217,937
208,054
199,725
188,352
190,353
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000190,353188,352199,725208,054217,937228,356239,842250,307260,552272,750284,906296,148304,003315,749321,919330,119334,928165,777173,052179,988185,65371,05346,23747,22139,99369,27970,93837,89567,30566,69956,87072,50074,95272,67071,57973,80674,62377,58578,08578,84880,529100,752103,059110,410110,97289,59787,72789,94997,678106,125129,102
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,212
14,082
13,845
11,393
11,512
8,831
11,702
8,909
18,195
16,717
27,600
31,362
28,210
27,222
34,898
19,170
17,125
17,936
37,964
33,527
33,52737,96417,93617,12519,17034,89827,22228,21031,36227,60016,71718,1958,90911,7028,83111,51211,39313,84514,08219,21200000000000000000000000000000000000000000000000
> Total Liabilities 
991,572
1,046,719
1,307,485
1,590,943
1,989,044
1,564,867
1,818,372
1,760,366
1,634,251
1,560,834
1,490,862
1,416,679
1,554,492
1,491,643
1,552,439
1,562,878
1,563,312
1,491,022
1,962,134
1,475,053
1,612,618
1,747,000
1,825,727
1,838,622
1,951,735
1,990,131
2,209,409
2,135,021
2,289,285
2,179,720
2,385,360
2,217,775
2,346,705
2,187,610
2,426,263
2,330,622
2,501,041
2,595,926
2,424,361
2,291,881
2,326,033
2,342,560
2,416,336
2,396,350
2,514,500
2,457,645
2,455,301
2,482,833
2,915,463
2,811,011
2,713,713
3,004,631
3,143,760
3,024,461
2,983,092
3,277,962
3,095,034
3,078,699
3,143,748
3,197,781
3,037,079
2,894,016
2,968,343
2,678,976
2,784,631
2,894,079
2,853,207
2,853,2072,894,0792,784,6312,678,9762,968,3432,894,0163,037,0793,197,7813,143,7483,078,6993,095,0343,277,9622,983,0923,024,4613,143,7603,004,6312,713,7132,811,0112,915,4632,482,8332,455,3012,457,6452,514,5002,396,3502,416,3362,342,5602,326,0332,291,8812,424,3612,595,9262,501,0412,330,6222,426,2632,187,6102,346,7052,217,7752,385,3602,179,7202,289,2852,135,0212,209,4091,990,1311,951,7351,838,6221,825,7271,747,0001,612,6181,475,0531,962,1341,491,0221,563,3121,562,8781,552,4391,491,6431,554,4921,416,6791,490,8621,560,8341,634,2511,760,3661,818,3721,564,8671,989,0441,590,9431,307,4851,046,719991,572
   > Total Current Liabilities 
756,191
802,811
1,063,859
1,179,399
1,234,684
861,166
1,119,850
1,045,326
745,092
776,526
757,042
638,579
782,294
761,074
629,776
595,536
684,615
999,109
1,097,514
620,808
679,679
632,895
734,154
736,792
815,952
1,128,695
1,219,497
871,181
912,572
782,359
1,133,994
983,981
1,063,699
908,722
1,022,328
993,195
998,554
1,059,031
933,552
841,544
829,505
837,385
851,349
901,051
1,031,845
938,925
889,302
969,171
1,409,519
1,367,267
1,155,803
1,496,499
1,591,997
1,356,958
1,329,897
1,649,450
1,483,204
1,481,622
1,534,499
1,453,487
1,316,853
1,249,845
1,445,911
1,172,229
1,293,051
1,242,054
1,204,694
1,204,6941,242,0541,293,0511,172,2291,445,9111,249,8451,316,8531,453,4871,534,4991,481,6221,483,2041,649,4501,329,8971,356,9581,591,9971,496,4991,155,8031,367,2671,409,519969,171889,302938,9251,031,845901,051851,349837,385829,505841,544933,5521,059,031998,554993,1951,022,328908,7221,063,699983,9811,133,994782,359912,572871,1811,219,4971,128,695815,952736,792734,154632,895679,679620,8081,097,514999,109684,615595,536629,776761,074782,294638,579757,042776,526745,0921,045,3261,119,850861,1661,234,6841,179,3991,063,859802,811756,191
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,698,643
1,683,509
1,695,572
81,178
81,601
81,822
82,583
82,192
82,128
389,261
730,798
710,683
528,914
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000528,914710,683730,798389,26182,12882,19282,58381,82281,60181,1781,695,5721,683,5091,698,64300000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,698,643
1,683,509
1,695,572
81,178
81,601
81,822
82,583
82,192
82,128
389,261
730,798
710,683
528,914
896,762
777,916
593,733
552,745
842,761
742,675
612,759
587,163
537,206
397,393
430,951
497,899
347,650
341,538
447,709
450,878
450,878447,709341,538347,650497,899430,951397,393537,206587,163612,759742,675842,761552,745593,733777,916896,762528,914710,683730,798389,26182,12882,19282,58381,82281,60181,1781,695,5721,683,5091,698,64300000000000000000000000000000000000000
       Accounts payable 
150,860
166,292
221,616
191,666
222,783
194,774
208,237
217,760
180,362
172,060
205,747
197,556
166,981
170,814
161,633
165,513
178,226
148,428
166,818
164,023
169,027
184,238
201,668
204,395
178,687
201,722
290,968
229,879
217,658
225,299
223,136
173,999
173,617
185,106
207,227
192,384
177,605
167,481
185,992
170,952
165,408
180,692
157,014
196,684
217,677
213,356
183,075
225,713
263,193
234,927
211,709
209,674
252,250
224,354
194,961
227,367
216,983
215,774
201,424
195,219
265,586
289,151
323,740
289,591
276,265
277,844
291,208
291,208277,844276,265289,591323,740289,151265,586195,219201,424215,774216,983227,367194,961224,354252,250209,674211,709234,927263,193225,713183,075213,356217,677196,684157,014180,692165,408170,952185,992167,481177,605192,384207,227185,106173,617173,999223,136225,299217,658229,879290,968201,722178,687204,395201,668184,238169,027164,023166,818148,428178,226165,513161,633170,814166,981197,556205,747172,060180,362217,760208,237194,774222,783191,666221,616166,292150,860
       Other Current Liabilities 
126,847
183,307
189,361
173,770
228,779
163,299
241,271
219,679
273,112
235,964
261,528
252,206
377,544
234,073
276,877
277,018
324,015
278,626
287,433
263,420
277,184
255,185
274,273
319,968
358,376
315,765
462,570
409,139
506,185
369,543
532,786
432,074
482,336
339,531
412,307
367,896
398,377
355,518
360,515
282,225
310,045
297,515
350,734
320,545
349,585
311,377
369,099
30,369
34,551
41,128
416,892
393,101
485,140
446,657
490,474
487,517
461,566
591,725
684,792
632,429
568,322
530,236
675,171
50,164
676,309
38,723
37,361
37,36138,723676,30950,164675,171530,236568,322632,429684,792591,725461,566487,517490,474446,657485,140393,101416,89241,12834,55130,369369,099311,377349,585320,545350,734297,515310,045282,225360,515355,518398,377367,896412,307339,531482,336432,074532,786369,543506,185409,139462,570315,765358,376319,968274,273255,185277,184263,420287,433278,626324,015277,018276,877234,073377,544252,206261,528235,964273,112219,679241,271163,299228,779173,770189,361183,307126,847
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,513,662
1,505,944
1,443,744
1,557,910
1,508,132
1,551,763
1,667,503
1,653,195
1,628,512
1,611,830
1,597,077
1,609,249
1,744,294
1,720,226
1,644,171
1,522,432
1,506,747
1,491,580
1,652,025
1,648,513
1,648,5131,652,0251,491,5801,506,7471,522,4321,644,1711,720,2261,744,2941,609,2491,597,0771,611,8301,628,5121,653,1951,667,5031,551,7631,508,1321,557,9101,443,7441,505,9441,513,66200000000000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
68,717
71,217
73,214
78,557
81,226
76,611
76,663
75,938
75,348
74,976
75,798
72,406
74,164
73,210
70,212
70,836
70,057
68,219
120,973
118,819
118,819120,97368,21970,05770,83670,21273,21074,16472,40675,79874,97675,34875,93876,66376,61181,22678,55773,21471,21768,71700000000000000000000000000000000000000000000000
> Total Stockholder Equity
1,217,521
1,482,929
1,521,688
1,557,708
1,521,977
1,601,055
1,608,140
1,658,353
1,767,358
1,882,320
1,949,992
2,006,514
1,992,907
2,036,496
2,026,723
2,059,479
1,990,475
2,046,054
2,526,257
2,538,945
2,523,549
2,583,440
2,583,245
2,855,343
2,826,277
2,958,526
3,008,164
3,090,638
3,024,052
2,997,963
3,304,230
3,357,075
3,167,773
3,153,529
3,218,872
3,185,543
3,124,182
3,075,209
3,091,731
3,044,790
3,037,189
3,069,217
3,074,832
3,092,242
3,037,761
2,935,277
2,926,094
2,953,633
2,899,515
2,767,721
2,783,151
2,802,163
2,668,696
2,697,928
2,744,430
2,663,495
2,757,098
2,731,359
2,722,239
2,809,209
2,847,044
2,920,302
2,930,230
3,012,955
2,930,854
3,027,082
3,098,338
3,098,3383,027,0822,930,8543,012,9552,930,2302,920,3022,847,0442,809,2092,722,2392,731,3592,757,0982,663,4952,744,4302,697,9282,668,6962,802,1632,783,1512,767,7212,899,5152,953,6332,926,0942,935,2773,037,7613,092,2423,074,8323,069,2173,037,1893,044,7903,091,7313,075,2093,124,1823,185,5433,218,8723,153,5293,167,7733,357,0753,304,2302,997,9633,024,0523,090,6383,008,1642,958,5262,826,2772,855,3432,583,2452,583,4402,523,5492,538,9452,526,2572,046,0541,990,4752,059,4792,026,7232,036,4961,992,9072,006,5141,949,9921,882,3201,767,3581,658,3531,608,1401,601,0551,521,9771,557,7081,521,6881,482,9291,217,521
   Common Stock
821,757
979,280
1,057,622
1,057,622
1,066,242
1,068,932
1,069,192
1,069,192
1,129,895
1,144,831
1,182,625
1,209,507
1,209,887
1,274,720
1,276,512
1,277,682
1,279,032
1,279,032
1,488,512
1,491,742
1,493,252
1,493,252
1,493,252
1,493,252
1,493,252
1,493,252
1,493,252
1,493,252
1,493,252
1,612,712
1,612,712
1,612,712
1,612,712
1,612,712
1,612,712
1,612,712
1,612,712
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
1,677,221
0
1,677,221
0
0
001,677,22101,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,677,2211,612,7121,612,7121,612,7121,612,7121,612,7121,612,7121,612,7121,612,7121,493,2521,493,2521,493,2521,493,2521,493,2521,493,2521,493,2521,493,2521,493,2521,491,7421,488,5121,279,0321,279,0321,277,6821,276,5121,274,7201,209,8871,209,5071,182,6251,144,8311,129,8951,069,1921,069,1921,068,9321,066,2421,057,6221,057,622979,280821,757
   Retained Earnings 
109,299
143,323
66,677
113,819
45,302
47,726
58,907
93,267
88,579
115,897
145,699
180,801
130,906
101,825
124,636
144,875
62,280
75,893
91,155
112,969
77,083
133,108
139,772
452,888
421,941
511,046
551,204
612,116
443,269
421,365
471,365
445,024
306,303
289,539
352,592
336,157
236,911
230,717
284,429
275,603
268,139
282,150
295,205
329,922
295,054
280,685
279,754
73,522
-7,923
-18,105
275,809
302,580
311,121
301,356
244,809
249,843
255,149
221,710
210,681
268,776
355,981
424,059
444,405
313,839
465,839
277,658
369,802
369,802277,658465,839313,839444,405424,059355,981268,776210,681221,710255,149249,843244,809301,356311,121302,580275,809-18,105-7,92373,522279,754280,685295,054329,922295,205282,150268,139275,603284,429230,717236,911336,157352,592289,539306,303445,024471,365421,365443,269612,116551,204511,046421,941452,888139,772133,10877,083112,96991,15575,89362,280144,875124,636101,825130,906180,801145,699115,89788,57993,26758,90747,72645,302113,81966,677143,323109,299
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 00-142,1780-121,368-110,950-116,130-100,304-129,179-131,088-129,565-123,787-118,991-134,790-143,865-136,412-128,898-110,694-76,197-63,582-76,829-68,577-47,117-27,504-29,141-29,147-50,166-64,947-26,83200000000000000000000000000000000000000



Balance Sheet

Currency in TWD. All numbers in thousands.




Cash Flow

Currency in TWD. All numbers in thousands.




Income Statement

Currency in TWD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue2,962,934
Cost of Revenue-1,871,691
Gross Profit1,091,2431,091,243
 
Operating Income (+$)
Gross Profit1,091,243
Operating Expense-2,675,197
Operating Income287,737-1,583,954
 
Operating Expense (+$)
Research Development132,580
Selling General Administrative670,926
Selling And Marketing Expenses0
Operating Expense2,675,197803,506
 
Net Interest Income (+$)
Interest Income12,307
Interest Expense-33,711
Other Finance Cost-0
Net Interest Income-21,404
 
Pretax Income (+$)
Operating Income287,737
Net Interest Income-21,404
Other Non-Operating Income Expenses0
Income Before Tax (EBT)305,708287,737
EBIT - interestExpense = -33,711
375,170
408,881
Interest Expense33,711
Earnings Before Interest and Taxes (EBIT)0339,419
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax305,708
Tax Provision--51,068
Net Income From Continuing Ops356,776356,776
Net Income375,170
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net021,404
 

Technical Analysis of Sinphar
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sinphar. The general trend of Sinphar is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sinphar's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Sinphar Pharmaceutical Co Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 41.10.

The bearish price targets are: 36.60 > 34.85 > 34.70.

Tweet this
Sinphar Pharmaceutical Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Sinphar Pharmaceutical Co Ltd. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Sinphar Pharmaceutical Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Sinphar Pharmaceutical Co Ltd. The current macd is 0.62593369.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sinphar price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Sinphar. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Sinphar price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Sinphar Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartSinphar Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Sinphar Pharmaceutical Co Ltd. The current adx is 31.07.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Sinphar shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Sinphar Pharmaceutical Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Sinphar Pharmaceutical Co Ltd. The current sar is 33.85.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Sinphar Pharmaceutical Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Sinphar Pharmaceutical Co Ltd. The current rsi is 62.75. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Sinphar Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) ChartSinphar Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Sinphar Pharmaceutical Co Ltd. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sinphar price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Sinphar Pharmaceutical Co Ltd Daily Stochastic Oscillator ChartSinphar Pharmaceutical Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Sinphar Pharmaceutical Co Ltd. The current cci is 121.18.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Sinphar Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) ChartSinphar Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Sinphar Pharmaceutical Co Ltd. The current cmo is 26.08.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Sinphar Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) ChartSinphar Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Sinphar Pharmaceutical Co Ltd. The current willr is -24.28571429.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Sinphar is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Sinphar Pharmaceutical Co Ltd Daily Williams %R ChartSinphar Pharmaceutical Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Sinphar Pharmaceutical Co Ltd.

Sinphar Pharmaceutical Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Sinphar Pharmaceutical Co Ltd. The current atr is 0.78186896.

Sinphar Pharmaceutical Co Ltd Daily Average True Range (ATR) ChartSinphar Pharmaceutical Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Sinphar Pharmaceutical Co Ltd. The current obv is 52,053,229.

Sinphar Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) ChartSinphar Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Sinphar Pharmaceutical Co Ltd. The current mfi is 64.87.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Sinphar Pharmaceutical Co Ltd Daily Money Flow Index (MFI) ChartSinphar Pharmaceutical Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Sinphar Pharmaceutical Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-10-31STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-02STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-09MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-23STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside

6.3. Candlestick Patterns

Sinphar Pharmaceutical Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Sinphar Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.749
Ma 20Greater thanMa 5035.280
Ma 50Greater thanMa 10033.962
Ma 100Greater thanMa 20033.699
OpenGreater thanClose36.650
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Sinphar with someone you think should read this too:
  • Are you bullish or bearish on Sinphar? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Sinphar? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Sinphar Pharmaceutical Co Ltd

I send you an email if I find something interesting about Sinphar Pharmaceutical Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Sinphar Pharmaceutical Co Ltd.

Receive notifications about Sinphar Pharmaceutical Co Ltd in your mailbox!